The RESTORE trial (NCT04945772) is a phase 2b randomized, shamcontrolled, multicentre, multidose, doublemasked clinical trial evaluating the efficacy and safety of MCO010 optogenetic therapy in adults with retinitis pigmentosa. MCO010 is an ambientlight activatable MultiCharacteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around the mechanism of action of MCO010, the results of the RESTORE trial and what the next steps in clinical development of MOC010 is.

The presentation entitled ‘Efficacy and safety of MCO010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, shamcontrolled, multicenter, multidose, doublemasked clinical trial (RESTORE)’ was presented at the Association for Research in Vision and Ophthalmology Annual Meeting, May 0509, 2023

Questions:

What is MCO010 and what is its mechanism of action? (0:19)
What are the aims, design, and eligibility criteria of the RESTORE study? (1:18)
What were the efficacy and safety findings? (2:37)
What will be the next steps in the clinical development of MCO010? (3:38)
Disclosures: David Boyer has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Filmed in coverage of the virtual ARVO 2023.